The MRF Applauds FDA’s Commitment to Proposed Tanning Bed Rules
April 8, 2022The MRF is proud to join our fellow members of the National Council on Skin Cancer Prevention (NCSCP) in urging the U.S. Food and Drug Administration (FDA) to finalize proposed rules that would ban minors from using tanning beds and require that adult …
Jamie’s Story: TIL Saved My Life
March 31, 2022Guest blog post by Jamie Goldfarb, stage 4 melanoma survivor, clinical trial participant and melanoma advocate: I was diagnosed with stage 4 melanoma in January 2011. It was the day I was supposed to return to work from maternity leave. My son was jus …
Patient Perspective: Katie Doble’s Journey with TIL Therapy
March 31, 2022Guest blog post by Katie Doble, ocular melanoma (OM) survivor, MRF Courage Award recipient and OM advocate: TIL therapy has given my family and me next-level hope. At 31 years old, I received my first cancer diagnosis—primary uveal melanoma, meaning it …
Recent FDA Approvals for the Melanoma Community
March 23, 2022The Melanoma Research Foundation (MRF) is pleased to share recent significant achievements for the melanoma community. In March 2022, the U.S. Food and Drug Administration (FDA) granted Iovance Biotherapeutics, Inc. an Investigational New Drug Applicat …
FDA Grants Investigational New Drug Application for TIL Therapy
March 18, 2022On March 15, the U.S. Food and Drug Administration (FDA) granted Iovance Biotherapeutics, Inc. an Investigational New Drug Application (IND) for IOV-4001, its first genetically modified tumor-infiltrating lymphocytes (TIL) therapy to treat unresectable …
Recent Comments